Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Späth Florentin 1980 ) > (2022) > Progression pattern...

Tahiru, WidadUmeå universitet,Onkologi (författare)

Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome : a cohort study in 42 patients

Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

2022-02-23
BioMed Central (BMC),2022
electronicrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:umu-193007
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-193007URI
https://doi.org/10.1186/s40164-022-00259-0DOI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Follow-up of low-risk monoclonal gammopathy of undetermined significance (MGUS) is debated as multiple myeloma (MM) progression risk is low. Worse MM outcome was reported for patients followed for low-risk MGUS, possibly due to less optimal follow-up. However, it is unknown whether progressing low-risk MGUS is associated with aggressive tumor behavior. Understanding these patterns is crucial for MGUS management. Here, we investigated whether progression from low-risk MGUS is associated with worse MM outcome in patients who had no MGUS follow-up before myeloma diagnosis. We retrospectively determined the MGUS status in repeated pre-diagnostic blood samples prospectively collected from 42 myeloma patients in median 11.6 years (first sample) and 3.3 years (repeated sample) before myeloma diagnosis. At first pre-diagnostic blood draw, 12 had low-risk (defined by an immunoglobulin [Ig] G monoclonal [M] spike < 15 g/L and a normal free light-chain ratio) and 30 had MGUS of other risk. MM bone disease was more common in patients with low-risk MGUS at first blood draw (67% vs. 30%, P = 0.041). Median survival since myeloma diagnosis was worse in low-risk than other MGUS at first blood draw (2.3 vs. 7.5 years, P = 0.004). Modest progression was observed between first and repeated blood draw for the majority of low-risk MGUS as 67% remained as low- or low-intermediate-risk MGUS at repeated blood draw. Our study, albeit limited by its small size, indicates that progression from low-risk MGUS is associated with worse MM outcome regardless of MGUS follow-up. Although further investigation is needed, progressing low-risk MGUS could belong to a group of aggressive tumors with progression that is difficult to predict.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
Aggressive myeloma
Low-risk MGUS
MGUS
MGUS follow-up
MGUS progression
Multiple myeloma
Myeloma outcome
NSHDS
Prospective blood samples

Biuppslag (personer, institutioner, konferenser, titlar ...)

Izarra Santamaria, AntonioUmeå universitet,Onkologi (författare)
Hultdin, JohanUmeå universitet,Klinisk kemi(Swepub:umu)johu0007 (författare)
Wu, Wendy Yi-YingUmeå universitet,Onkologi(Swepub:umu)weyi0002 (författare)
Späth, Florentin,1980-Umeå universitet,Onkologi(Swepub:umu)flsp0001 (författare)
Umeå universitetOnkologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:Experimental Hematology & Oncology: BioMed Central (BMC)11:12162-3619

Internetlänk

Hitta via bibliotek

Experimental Hematology & Oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Tahiru, Widad; Izarra Santamari ...; Hultdin, Johan; Wu, Wendy Yi-Yin ...; Späth, Florentin ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Experimental Hem ...

Av lärosätet: Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se